Rate of change in carotid intima-media thickness and vascular events: Meta-analyses can not solve all the issues. A point of view

Journal of Hypertension

Volumn 30, Issue 9, 2012, Pages 1690-1696

  Bots, Michiel L ^a   Taylor, Allen J ^b   Kastelein, John J P ^c   Peters, Sanne A E ^a   Den Ruijter, Hester M ^a   Tegeler, Charles H ^d   Baldassarre, Damiano ^e   Stein, James H ^f   O'Leary, Daniel H ^g   Revkin, James H ^h   Grobbee, Diederick E ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MILAN   (Italy)

^f UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^g TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

atherosclerosis; carotid intima media thickness; prevention; surrogacy; trial

Indexed keywords

ESTROGEN;

ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE MARKER; FIBRINOLYSIS; HEMOSTASIS; HUMAN; META ANALYSIS (TOPIC); PRIORITY JOURNAL; REVIEW; RISK REDUCTION;

EID: 84865529096     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32835644dc     Document Type: Review

References (37)

1. Revkin JH, Shear CL, Pouleur HG, Ryder SW, Orloff DG. Biomarkers in the prevention and treatment of atherosclerosis: need, validation, and future. Pharmacol Rev 2007; 59:40-53. (Pubitemid 46333995)
2. Bots ML, Evans GW, Riley WA, Grobbee DE. Carotid intima-media thickness measurements in intervention studies: design options, progression rates, and sample size considerations: a point of view. Stroke 2003; 34:2985-2994. (Pubitemid 37517782)
3. Domanski M, Pocock S, Bernaud C, Borer J, Geller N, Revkin J, Zannad F. Surrogate endpoints in randomized cardiovascular clinical trials. Fundam Clin Pharmacol 2011; 25:411-413.
4. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989; 8:431-440. (Pubitemid 19105891)
5. Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu CR, Liu CH, Azen SP. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998; 128:262-269. (Pubitemid 28090756)
6. Zanchetti A, Hennig M, Hollweck R, Bond G, Tang R, Cuspidi C, et al. Baseline values but not treatment-induced changes in carotid intimamedia thickness predict incident cardiovascular events in treated hypertensive patients: findings in the European Lacidipine Study on Atherosclerosis (ELSA). Circulation 2009; 120:1084-1090.
7. Goldberger ZD, Valle JA, Dandekar VK, Chan PS, Ko DT, Nallamothu BK. Are changes in carotid intima-media thickness related to risk of nonfatal myocardial infarction? A critical review and meta-regression analysis. Am Heart J 2010; 160:701-714.
8. Costanzo P, Perrone-Filardi P, Vassallo E, Paolillo S, Cesarano P, Brevetti G, Chiariello M. Does carotid intima-media thickness regression predict reduction of cardiovascular events? A meta-analysis of 41 randomized trials. J Am Coll Cardiol 2010; 56:2006-2020.
9. Zanchetti A. Hypertension: meta-analyses: first-rank evidence or second-hand information? Nat Rev Cardiol 2011; 8:249-251.
10. Czernichow S, Zanchetti A, Turnbull F, Barzi F, Ninomiya T, Kengne AP, et al., Blood Pressure Lowering Treatment Trialists' Collaboration. The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. J Hypertens 2011; 29:4-16.
11. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010; 376:1670-1681.
12. Cho L, Mukherjee D. Hormone replacement therapy and secondary cardiovascular prevention: a meta-analysis of randomized trials. Cardiology 2005; 104:143-147. (Pubitemid 41291530)
13. Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, et al. ILLUSTRATE Investigators, Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007; 356:1304-1316. (Pubitemid 46513296)
14. Kastelein JJ, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, et al. RADIANCE 1 Investigators, Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007; 356:1620-1630. (Pubitemid 46631671)
15. Bots ML, Visseren FL, Evans GW, Riley WA, Revkin JH, Tegeler CH, et al. RADIANCE 2 Investigators, Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007; 370:153-160. (Pubitemid 47042895)
16. Dogan S, Duivenvoorden R, Grobbee DE, Kastelein JJ, Shear CL, Evans GW, et al. Radiance 1 and Radiance 2 Study Groups. Ultrasound protocols to measure carotid intima-media thickness in trials; comparison of reproducibility, rate of progression, and effect of intervention in subjects with familial hypercholesterolemia and subjects with mixed dyslipidemia. Ann Med 2010; 42:447-464.
17. Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, Sharrett AR, Clegg LX. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol 1997; 146:483-494. (Pubitemid 27391409)
18. Blankenhorn DH, Johnson RL, Nessim SA, Azen SP, Sanmarco ME, Selzer RH. The Cholesterol Lowering Atherosclerosis Study (CLAS): design, methods, and baseline results. Control Clin Trials 1987; 8:356-387. (Pubitemid 18040817)
19. Dogan S, Plantinga Y, Dijk JM, van der Graaf Y, Grobbee DE, Bots ML. SMART Study Group. Manual B-mode versus automated radiofrequency carotid intima-media thickness measurements. J Am Soc Echocardiogr 2009; 22:1137-1144.
20. Schreuder FH, Graf M, Hameleers JM, Mess WH, Hoeks AP. Measurement of common carotid artery intima-media thickness in clinical practice: comparison of B-mode and RF-based technique. Ultraschall Med 2009; 30:459-465.
21. Baldassarre D, Tremoli E, Amato M, Veglia F, Bondioli A, Sirtori CR. Reproducibility validation study comparing analog and digital imaging technologies for the measurement of intima-media thickness. Stroke 2000 ;31:1104-1110. (Pubitemid 30253532)
22. Kanters SD, Elgersma OE, Banga JD, van Leeuwen MS, Algra A. Reproducibility of measurements of intima-media thickness and distensibility in the common carotid artery. Eur J Vasc Endovasc Surg 1998; 16:28-35. (Pubitemid 28379128)
23. Ioannidis JP. Why most discovered true associations are inflated. Epidemiology 2008; 19:640-648.
24. Polak JF, Person SD, Wei GS, Godreau A, Jacobs DR Jr, Harrington A, et al. Segment-specific associations of carotid intima-media thickness with cardiovascular risk factors: the Coronary Artery Risk Development in Young Adults (CARDIA) study. Stroke 2010; 41:9-15.
25. Berglund GL, Riley WA, Barnes RW, Furberg CD. Quality control in ultrasound studies on atherosclerosis. J Intern Med 1994; 236:581-586. (Pubitemid 24340018)
26. Peters SA, den Ruijter HM, Palmer MK, Grobbee DE, Crouse JR 3rd, O'Leary DH, et al.; METEOR Study Group. Manual or semi-automated edge detection of the maximal far wall common carotid intima-media thickness: a direct comparison. J Intern Med 2012; 271:247-256.
27. Crouse JR 3rd, Raichlen JS, Riley WA, Evans GW, Palmer MK, O'leary DH, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR trial. JAMA 2007; 297:1344-1353. (Pubitemid 46513235)
28. Groenwold RH, Donders AR, van der Heijden GJ, Hoes AW, Rovers MM. Confounding of subgroup analyses in randomized data. Arch Intern Med 2009; 169:1532-1534.
29. Koopman L, van der Heijden GJ, Glasziou PP, Grobbee DE, Rovers MM. A systematic review of analytical methods used to study subgroups in (individual patient data) meta-analyses. J Clin Epidemiol 2007; 60:1002-1009.
30. Deeks JJ. Systematic reviews of published evidence: miracles or minefields? Ann Oncol 1998; 9:703-709. (Pubitemid 28394154)
31. Robinson WS. Ecological correlations and the behavior of individuals. Int J Epidemiol 2009; 38:337-341.
32. Kinlay S. Low-density lipoprotein-dependent and-independent effects of cholesterol-lowering therapies on C-reactive protein: a metaanalysis. J Am Coll Cardiol 2007; 49:2003-2009. (Pubitemid 46734641)
33. Peters SA, Palmer MK, Grobbee DE. Crouse JR 3rd, O'Leary DH, Raichlen JS, Bots ML. C-reactive protein lowering with rosuvastatin in the METEOR study. J Intern Med 2010; 268:155-161.
34. Lorenz MW, Bickel H, Bots ML, Breteler MM, Catapano AL, Desvarieux M, et al. Individual progression of carotid intima media thickness as a surrogate for vascular risk (PROG-IMT): rationale and design of a metaanalysis project. Am Heart J 2010; 159:730-736.
35. Lorenz MW, Polak JF, Kavousi M, Mathiesen EB, Völzke H, Tuomainen TP, et al.; on behalf of the PROG-IMT Study Group. Carotid intimamedia thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a metaanalysis of individual participant data. Lancet 2012; 379:2053-2062.
36. Lubsen J, Kirwan BA. Combined endpoints: can we use them? Stat Med 2002; 21:2959-2970.
37. Dogan S, Kastelein JJ, Grobbee DE, Bots ML. Mean common or mean maximum carotid intima-media thickness as primary outcome in lipidmodifying intervention studies. J Atheroscler Thromb 2011; 18:946-957.